29 67

Cited 8 times in

Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma

DC Field Value Language
dc.contributor.author이용준-
dc.date.accessioned2024-03-22T05:52:21Z-
dc.date.available2024-03-22T05:52:21Z-
dc.date.issued2023-02-
dc.identifier.issn0340-7004-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/198267-
dc.description.abstractImmune checkpoint inhibitors are effective for advanced hepatocellular carcinoma (HCC), but there remains a need for peripheral blood biomarkers to predict the clinical response. Here, we analyzed the peripheral blood of 45 patients with advanced HCC who underwent nivolumab. During treatment, frequency of classical monocytes (CD14+CD16−) was increased on day 7, and the fold increase in the frequency on day 7 over day 0 (cMonocyteD7/D0) was significantly higher in patients with durable clinical benefit (DCB) than in patients with non-DCB (NDB). When we analyzed transcriptomes of classical monocytes, CD274, gene encoding PD-L1, was upregulated in NDB patients compared to DCB patients at day 7. Notably, gene signature of suppressive tumor-associated macrophages, or IL4l1+PD-L1+IDO1+ macrophages, was enriched after treatment in NDB patients, but not in DCB patients. Accordingly, the fold increase in the frequency of PD-L1+ classical monocytes at day 7 over day 0 (cMonocyte-PDL1D7/D0) was higher in NDB patients than DCB patients. The combined biomarker cMonocyteD7/D0/cMonocyte-PDL1D7/D0 was termed the “monocyte index”, which was significantly higher in DCB patients than NDB patients. Moreover, the monocyte index was an independent prognostic factor for survival. Overall, our results suggest that early changes of circulating classical monocytes, represented as a monocyte index, could predict clinical outcomes of advanced HCC patients undergoing anti-PD-1 therapy. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherSpringer Verlag-
dc.relation.isPartOfCANCER IMMUNOLOGY IMMUNOTHERAPY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHB7-H1 Antigen-
dc.subject.MESHCarcinoma, Hepatocellular* / pathology-
dc.subject.MESHHumans-
dc.subject.MESHLiver Neoplasms* / pathology-
dc.subject.MESHMacrophages-
dc.subject.MESHMonocytes-
dc.titleDynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorBradley J Monk-
dc.contributor.googleauthorTakafumi Toita-
dc.contributor.googleauthorXiaohua Wu-
dc.contributor.googleauthorJuan C Vázquez Limón-
dc.contributor.googleauthorRafal Tarnawski-
dc.contributor.googleauthorMasaki Mandai-
dc.contributor.googleauthorRonnie Shapira-Frommer-
dc.contributor.googleauthorUmesh Mahantshetty-
dc.contributor.googleauthorMaria Del Pilar Estevez-Diz-
dc.contributor.googleauthorQi Zhou-
dc.contributor.googleauthorSewanti Limaye-
dc.contributor.googleauthorFrancisco J Ramirez Godinez-
dc.contributor.googleauthorChristina Oppermann Kussler-
dc.contributor.googleauthorSzilvia Varga-
dc.contributor.googleauthorNatalia Valdiviezo-
dc.contributor.googleauthorDaisuke Aoki-
dc.contributor.googleauthorManuel Leiva-
dc.contributor.googleauthorJung-Yun Lee-
dc.contributor.googleauthorRaymond Sulay-
dc.contributor.googleauthorYulia Kreynina-
dc.contributor.googleauthorWen-Fang Cheng-
dc.contributor.googleauthorFelipe Rey-
dc.contributor.googleauthorYi Rong-
dc.contributor.googleauthorGuihao Ke-
dc.contributor.googleauthorSophie Wildsmith-
dc.contributor.googleauthorAndrew Lloyd-
dc.contributor.googleauthorHannah Dry-
dc.contributor.googleauthorAna Tablante Nunes-
dc.contributor.googleauthorJyoti Mayadev-
dc.identifier.doi10.1007/s00262-022-03258-6-
dc.contributor.localIdA02984-
dc.relation.journalcodeJ00445-
dc.identifier.eissn1432-0851-
dc.identifier.pmid35902399-
dc.subject.keywordAnti-PD-1 therapy-
dc.subject.keywordBiomarker-
dc.subject.keywordClassical monocyte-
dc.subject.keywordHepatocellular carcinoma-
dc.subject.keywordNivolumab-
dc.contributor.alternativeNameLee, Yong-Joon-
dc.contributor.affiliatedAuthor이용준-
dc.citation.volume72-
dc.citation.number2-
dc.citation.startPage371-
dc.citation.endPage384-
dc.identifier.bibliographicCitationCANCER IMMUNOLOGY IMMUNOTHERAPY, Vol.72(2) : 371-384, 2023-02-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.